Suitability of endobronchial ultrasound-guided transbronchial needle aspiration specimens for subtyping and genotyping of non-small cell lung cancer: A multicenter study of 774 patients

American Journal of Respiratory and Critical Care Medicine

Volumn 185, Issue 12, 2012, Pages 1316-1322

  Navani, Neal ^a,b,c   Brown, James M ^a,b   Nankivell, Matthew ^c   Woolhouse, Ian ^d   Harrison, Richard N ^e   Jeebun, Vandana ^e   Munavvar, Mohammed ^f   Ng, Benjamin J ^g   Rassl, Doris M ^g   Falzon, Mary ^b   Kocjan, Gabrijela ^b   Rintoul, Robert C ^g   Nicholson, Andrew G ^h   Janes, Sam M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY HOSPITAL OF NORTH TEES   (United Kingdom)

^f LANCASHIRE TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g PAPWORTH HOSPITAL   (United Kingdom)

^h NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Adenocarcinoma; EGFR mutation; Endobronchial ultrasound; Non small cell lung cancer; NSCLC NOS

Indexed keywords

GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; ENDOBRONCHIAL ULTRASONOGRAPHY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; TRANSBRONCHIAL ASPIRATION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOPSY, FINE-NEEDLE; BRONCHOSCOPY; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; CONFIDENCE INTERVALS; CYTODIAGNOSIS; ENDOSONOGRAPHY; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 84862513803     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201202-0294OC     Document Type: Article

References (37)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
2. National Institute of Health and Clinical Excellence. Pemetrexed for the first-line treatment of non-small-cell lung cancer [Internet; accessed 2012 Jan 13]. Available from: www.nice.org.uk/TA181
3. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III, Gaudreault J, Damico LA, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191. (Pubitemid 41095154)
4. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
5. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12:735-742.
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
7. Navani N, Spiro SG, Janes SM. Mediastinal staging of NSCLC with endoscopic and endobronchial ultrasound. Nat Rev Clin Oncol 2009;6:278-286.
8. Wallace WA, Monaghan HM, Salter DM, Gibbons MA, Skwarski KM. Endobronchial ultrasound-guided fine-needle aspiration and liquid-based thin-layer cytology. J Clin Pathol 2007;60:388-391. (Pubitemid 46596557)
9. Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-830. (Pubitemid 33108152)
10. Khayyata S, Yun S, Pasha T, Jian B, McGrath C, Yu G, Gupta P, Baloch Z. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn Cytopathol 2009;37:178-183.
11. Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-773. (Pubitemid 34546942)
12. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 2004;57:383-387. (Pubitemid 38446256)
13. Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non-small cell lung cancer histologies. J Thorac Oncol 2009;4:1202-1211.
14. NHS Information Centre. National lung cancer audit [Internet; accessed 2012 Jan 13]. Available from: http://www.ic.nhs.uk/webfiles/Services/NCASP/ audits%20and%20reports/NHSIC-National-Lung-Cancer-Audit-2010-V1.0.pdf
15. Tournoy KG, Rintoul RC, van Meerbeeck JP, Carroll NR, Praet M, Buttery RC, van Kralingen KW, Rabe KF, Annema JT. EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. Lung Cancer 2009;63:45-49.
16. Fischer AH, Cibas ES, Howell LP, Kurian EM, Laucirica R, Moriarty AT, Renshaw AA, Zakowski MF, Young NA. Role of cytology in the management of non-small-cell lung cancer. J Clin Oncol 2011;29:3331-3332.
17. Wallace WA, Rassl DM. Accuracy of cell typing in nonsmall cell lung cancer by EBUS/EUS-FNA cytological samples. Eur Respir J 2011;38:911-917.
18. Sigel CS, Moreira AL, TravisWD, Zakowski MF, Thornton RH, Riely GJ, Rekhtman N. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol 2011;6:1849-1856.
19. Nizzoli R, Tiseo M, Gelsomino F, Bartolotti M, Majori M, Ferrari L, De Filippo M, Rindi G, Silini EM, Guazzi A, et al. Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer. J Thorac Oncol 2011;6:489-493.
20. Travis WD. BEM-HH-KealE. WHO classification: pathology and genetics: tumours of the lung, pleura, thymus, and heart. Lyon, France: IARC Press; 2004.
21. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
22. Felip E, Gridelli C, Baas P, Rosell R, Stahel R. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22:1507-1519.
23. Vincek V, Nassiri M, Nadji M, Morales AR. A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest 2003;83:1427-1435. (Pubitemid 37267826)
24. van Eijk R, Licht J, Schrumpf M, Talebian YM, Ruano D, Forte GI, Nederlof PM, Veselic M, Rabe KF, Annema JT, et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS ONE 2011;6:e17791.
25. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010;5:1664-1667.
26. Garcia-Olive I, Monso E, Andreo F, Sanz-Santos J, Taron M, Molina-Vila MA, Llatjos M, Castella E, Moran T, Bertran-Alamillo J, et al. Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J 2010;35:391-395.
27. Billah S, Stewart J, Staerkel G, Chen S, Gong Y, Guo M. EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens. Cancer Cytopathol 2011;119:111-117.
28. Nakajima T, Yasufuku K, Suzuki M, Hiroshima K, Kubo R, Mohammed S, Miyagi Y, Matsukuma S, Sekine Y, Fujisawa T. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2007;132:597-602. (Pubitemid 47282394)
29. Nakajima T, Yasufuku K, Nakagawara A, Kimura H, Yoshino I. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011;140:1319-1324.
30. Rekhtman N, Brandt SM, Sigel CS, Friedlander MA, Riely GJ, Travis WD, Zakowski MF, Moreira AL. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011;6:451-458.
31. Anraku M, Waddell TK. Surgery for small-cell lung cancer. Semin Thorac Cardiovasc Surg 2006;18:211-216. (Pubitemid 44914573)
32. Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res 2011;30:30.
33. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009;4:809-815.
34. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009;15:4554-4560.
35. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011;29:2972-2977.
36. Gu P, Zhao YZ, Jiang LY, Zhang W, Xin Y, Han BH. Endobronchial ultrasound-guided transbronchial needle aspiration for staging of lung cancer: a systematic review and meta-analysis. Eur J Cancer 2009;45:1389-1396.
37. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-285.